ADM deal gives Nutraceutix 'freedom to focus on OTC'

- Last updated on GMT

Related tags: Dietary supplement, Adm

Nutraceutix president and CEO, David T. Howard, has said that his company's recent alliance with agrifood giant Archer Daniel Midlands (ADM)...

Nutraceutix president and CEO, David T. Howard, has said that his company's recent alliance with agrifood giant Archer Daniel Midlands (ADM) "validates the Nutraceutix CDT platform and gives the company freedom to concentrate on OTC partnerships."

The two companies announced on 29 March an exclusive licensing agreement​ for ADM to use Nutraceutix's patented Controlled Delivery Technology (CDT) to develop and market dietary supplements.

Howard explained that the alliance, which gives ADM exclusive rights to market its products using Nutraceutix's CDT technology to dietary supplement manufacturers the world over, means that Nutraceutix no longer needs to pursue other nutraceutical alliances.

"Our partnership with ADM allows us the freedom to now focus our resources on and pursue partnerships with OTC and pharmaceutical companies to incorporate CDT technology into products for their respective markets,"​ he said.

The first product to be marketed by ADM is Novasoy Daily Dose, a product which contains natural-based soy isoflavones.

Howard claimed that the latest research from Frost & Sullivan (which highlights the currently booming isoflavone sales in the US - $470 million in 2001) was a positive sign for the product, although ADM had not yet provided estimates for market size or market share.

He added: "The ability of the CDT technology platform to improve the way soy isoflavones are available to the body, particularly when there are long periods between dosings, is an important advantage in this exploding market."

Nutraceutix will be working closely with ADM on its market roll-out plans for the introduction of Novasoy Daily Dose. The Novasoy brand is already well established in the US where it is incorporated into more than 50 nutritional supplements marketed to support a range of health benefits.

Howard also said that securing an early income stream was part of the refocused Nutraceutix business plan, "which calls for that revenue to help lower our burn rate as we pursue technology development and innovation with the OTC and pharmaceutical partnerships - the products from which can be very lucrative but which often take two to seven years to bring to fruition."

Nutraceutix has reportedly suffered dramatically from September 11, with reduced 4Q 2001 revenues. Howard claims that sales have increased steadily each month of the first quarter and expects March revenues to have returned to targeted levels.

Related topics: Proteins

Related products

show more

Discover next level pea protein performance with ADM.

Discover next level pea protein performance with ADM.

ADM brings innovation to the table. | 22-Nov-2021 | Infographic

The flexitarian lifestyle continues to gain momentum, fueling growth for plant-based foods and beverages. Discover what’s driving consumer demand for plant-forward...

Plant-Based Dairy Alternative Beverages

Plant-Based Dairy Alternative Beverages

CP Kelco | 11-Nov-2021 | Technical / White Paper

The market has been evolving rapidly thanks to the variety of new plant protein bases available, ranging from almond, cashew and soy to oat, pea, coconut...

Unlock crave-worthy snacking success.

Unlock crave-worthy snacking success.

ADM | 21-Oct-2021 | Case Study

Today's consumers crave snacks that deliver it all - quality taste with positive nutrition and added health benefits. ADM is at the forefront of...

Forecast: The Future is Plant-Based

Forecast: The Future is Plant-Based

Nellson | 05-Oct-2021 | Technical / White Paper

Find out what’s driving today’s nutrition-focused consumers—and how you can stay ahead of what they will want next. How quickly and dramatically is the...

Related suppliers

Follow us

Products

View more

Webinars